Cancer Network spoke with Daniel McFarland, DO, of Memorial Sloan Kettering Cancer Center, about building programs to prevent burnout and suicide in oncology providers.
Cancer Network spoke with Daniel McFarland, DO, of Memorial Sloan Kettering Cancer Center, about building programs to prevent burnout and suicide in oncology providers.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.